Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 147.56M | 138.10M | 101.21M | 53.16M | 69.57M | 100.36M |
Gross Profit | 147.56M | 138.10M | 101.21M | 47.31M | 63.73M | 100.36M |
EBITDA | 37.65M | 26.76M | -4.31M | -98.89M | -113.34M | -77.97M |
Net Income | 41.60M | 31.87M | -569.00K | -97.30M | -80.65M | -32.88M |
Balance Sheet | ||||||
Total Assets | 98.50M | 120.53M | 201.79M | 260.89M | 339.41M | 358.66M |
Cash, Cash Equivalents and Short-Term Investments | 79.89M | 100.62M | 174.51M | 193.65M | 305.23M | 316.12M |
Total Debt | 8.15M | 9.38M | 13.97M | 18.06M | 18.06M | 24.87M |
Total Liabilities | 73.45M | 120.99M | 249.24M | 346.64M | 250.03M | 308.86M |
Stockholders Equity | 25.05M | -456.00K | -47.45M | -85.75M | 89.38M | 49.80M |
Cash Flow | ||||||
Free Cash Flow | -81.54M | -86.54M | -56.88M | -112.53M | -120.64M | 2.95M |
Operating Cash Flow | -81.23M | -86.23M | -56.03M | -110.79M | -119.03M | 5.26M |
Investing Cash Flow | 85.41M | 99.70M | -150.67M | 98.26M | 22.49M | -18.72M |
Financing Cash Flow | 7.35M | 7.52M | 30.23M | 648.00K | 110.21M | 16.89M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $371.80M | 4.76 | -58.97% | ― | 23.81% | 146.45% | |
63 Neutral | CHF22.83B | 15.22 | 10.81% | 2.15% | 47.85% | -11.82% | |
50 Neutral | $55.77M | ― | -119.22% | ― | ― | 25.51% | |
50 Neutral | $50.67M | ― | -221.66% | ― | 13.83% | 37.66% | |
45 Neutral | $80.32M | ― | -196.81% | ― | ― | ― | |
41 Neutral | $37.28M | ― | -68.14% | ― | ― | ― | |
36 Underperform | $38.57M | ― | -62.41% | ― | ― | 10.84% |
On June 11, 2025, CytomX Therapeutics held its Annual Meeting of Stockholders, where key amendments to the company’s equity and stock purchase plans were approved. The amendments included increasing the number of shares available under the 2015 Equity Incentive Plan, removing the evergreen provision, and extending the Employee Stock Purchase Plan indefinitely. Additionally, stockholders elected new directors, ratified the selection of Ernst & Young LLP as the independent auditor, and approved executive compensation.
The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.
CytomX Therapeutics announced that it has regained compliance with the Nasdaq’s Minimum Bid Price Requirement after its stock price closed at $1.00 or greater for 10 consecutive trading days as of May 23, 2025. This resolution of the compliance issue stabilizes the company’s market position and avoids potential delisting, which is crucial for maintaining investor confidence and operational stability.
The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.
On May 12, 2025, CytomX Therapeutics entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co. for the sale of 76,923,076 shares of common stock at $1.30 per share, resulting in estimated net proceeds of $93.4 million. The funds are intended for research and development, general corporate purposes, and working capital needs, potentially strengthening CytomX’s position in the biotechnology sector.
The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.
On May 12, 2025, CytomX Therapeutics announced positive interim Phase 1 data for its EpCAM PROBODY® ADC candidate, CX-2051, in advanced colorectal cancer. The data, as of April 7, 2025, showed a 28% overall response rate among efficacy-evaluable patients, with a 94% disease control rate and manageable adverse events. The company has commenced dose expansions and plans to initiate a Phase 2 study in the first half of 2026. CytomX ended the first quarter with $79.9 million in cash, extending its operational runway into the second quarter of 2026, and achieved a $5 million milestone payment from Astellas.